ASH: J&J links subcut BCMA bispecific to 73% response rate, plots aggressive investment

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Dec 06, 2020 at 07:22: PM
via A subcutaneous formulation of Johnson & Johnson’s BCMAxCD3 bispecific antibody teclistamab has achieved a 73% overall response rate in a small trial of heavily pretreated multiple myeloma patients.

article source
 




Top Bottom
Back
Quote